D70.1
BillableAgranulocytosis secondary to cancer chemotherapy
HCC Category Mapping
V24HCC 47 — Disorders of Immunity
0.472ESRDHCC 47 — Disorders of Immunity
0.000What This Code Means
A dangerous drop in white blood cells caused by cancer chemotherapy treatment that kills bone marrow cells.
Coding Tips
- •Always link this code to the underlying cancer diagnosis and the specific chemotherapy regimen when documented
- •This is a known adverse effect; ensure the chemotherapy treatment is documented in the medical record
Clinical Significance
Agranulocytosis secondary to cancer chemotherapy is a common and expected complication of cytotoxic treatment, characterized by severely reduced neutrophil counts that increase the risk of life-threatening infections. The severity and duration depend on the specific chemotherapy regimen, and management includes prophylactic or therapeutic G-CSF, infection surveillance, and sometimes hospitalization for febrile neutropenia.
Documentation Requirements
- ✓Document the specific chemotherapy regimen causing agranulocytosis, nadir absolute neutrophil count, timing relative to chemotherapy cycle, and whether febrile neutropenia developed.
- ✓Record G-CSF prophylaxis or treatment, any infectious complications, and the impact on subsequent chemotherapy dosing or scheduling.
Use Additional Code
- code for adverse effect, if applicable, to identify drug (T45.1X5)
Code Also
- underlying neoplasm
Commonly Confused Codes
D70.2 (Other drug-induced agranulocytosis) — for non-chemotherapy medicationsD70.0 (Congenital agranulocytosis) — inherited rather than treatment-relatedD70.9 (Neutropenia, unspecified) — should specify the chemotherapy-related causeD61.1 (Drug-induced aplastic anemia) — pancytopenia beyond isolated neutropenia.
Code Hierarchy
└D70Neutropenia└D70.1Agranulocytosis secondary to cancer chemotherapy
└D70.1Agranulocytosis secondary to cancer chemotherapy